SANA BIOTECHNOLOGY INC
NASDAQ: SANA (Sana Biotechnology, Inc.)
Kemas kini terakhir: 4 jam lalu5.00
0.06 (1.28%)
| Penutupan Terdahulu | 4.94 |
| Buka | 4.92 |
| Jumlah Dagangan | 4,706,292 |
| Purata Dagangan (3B) | 5,123,469 |
| Modal Pasaran | 1,331,830,528 |
| Harga / Buku (P/B) | 6.74 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Nov 2025 |
| EPS Cair (TTM) | -0.880 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 43.67% |
| Nisbah Semasa (MRQ) | 3.40 |
| Aliran Tunai Operasi (OCF TTM) | -206.18 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -118.45 M |
| Pulangan Atas Aset (ROA TTM) | -23.84% |
| Pulangan Atas Ekuiti (ROE TTM) | -71.44% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Sana Biotechnology, Inc. | Menurun | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | 1.0 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | 4.0 |
| Purata | -0.40 |
|
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 among others. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 8.46% |
| % Dimiliki oleh Institusi | 89.37% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Flagship Pioneering Inc. | 30 Sep 2025 | 25,001,856 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 9.00 (HC Wainwright & Co., 80.00%) | Beli |
| Median | 8.00 (60.00%) | |
| Rendah | 6.00 (Wedbush, 20.00%) | Beli |
| Purata | 7.67 (53.40%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 4.36 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 07 Nov 2025 | 9.00 (80.00%) | Beli | 4.09 |
| Wedbush | 07 Nov 2025 | 6.00 (20.00%) | Beli | 4.09 |
| 24 Sep 2025 | 5.00 (0.00%) | Beli | 3.41 | |
| Citizens | 30 Oct 2025 | 8.00 (60.00%) | Beli | 4.90 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| WYRICK SUSAN D. | - | 5.18 | -2,565 | -13,287 |
| Jumlah Keseluruhan Kuantiti Bersih | -2,565 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -13,287 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 5.18 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| WYRICK SUSAN D. | Pegawai | 04 Dec 2025 | Dibuang (-) | 2,565 | 5.18 | 13,287 |
| WYRICK SUSAN D. | Pegawai | 03 Dec 2025 | Pelaksanaan pilihan | 10,000 | - | - |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 08 Dec 2025 | Pengumuman | Sana Biotechnology Announces Publication in Nature Biotechnology of in vivo Gene Editing of Human Hematopoietic Stem Cells in Preclinical Models Using the Fusogen Platform |
| 24 Nov 2025 | Pengumuman | Sana Biotechnology to Present at December 2025 Investor Conferences |
| 06 Nov 2025 | Pengumuman | Sana Biotechnology Reports Third Quarter 2025 Financial Results and Business Updates |
| 04 Nov 2025 | Pengumuman | Sana Biotechnology to Present at the TD Cowen Immunology & Inflammation Summit |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |